
Opinion|Videos|November 12, 2024
New Data from AANEM 2024 in Generalized Myasthenia Gravis
Key Takeaways
- Gene therapy advancements for inherited neuromuscular disorders were a significant focus, highlighting potential transformative impacts on treatment paradigms.
- Novel pharmacological interventions targeting specific molecular pathways showed promise, indicating a shift towards more targeted therapeutic approaches.
Panelists discuss how recent data presented at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) conference may impact clinical practice for myasthenia gravis, highlighting emerging treatments they find particularly promising for future management of the condition.
Advertisement
Video content above is prompted by the following:
- Please share other interesting/practice-impacting data that were presented at AANEM 2024.
- What other emerging treatments are you excited about?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Apitegromab for Spinal Muscular Atrophy
2
AAN, AHS Issue Updated Guideline on Pharmacologic Migraine Prevention in Adults: FAQs
3
Once-Daily Trientine Enters Phase 3 Trial for First-Line Treatment in Wilson Disease
4
FDA Priority Review Puts Satralizumab on Track as First MOGAD Drug
5









